Eckert & Ziegler SE (VIE:EUZG)

Market Cap	769.69M -28.4%
Revenue (ttm)	312.50M +4.4%
Net Income	49.74M +35.7%
EPS	0.79 +36.4%
Shares Out	n/a
PE Ratio	15.48
Forward PE	14.75
Dividend	0.22 (1.76%)
Ex-Dividend Date	Jun 25, 2026

Volume	n/a
Open	12.34
Previous Close	12.31
Day's Range	12.33 - 12.44
52-Week Range	12.31 - 18.58
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Eckert & Ziegler SE

Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceu...

• Industry: Industrial Inorganic Chemicals
• Founded: 1992
• Employees: 1,105
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: EUZG

Financial Performance

In 2025, Eckert & Ziegler SE's revenue was 311.96 million, an increase of 5.45% compared to the previous year's 295.85 million. Earnings were 48.76 million, an increase of 46.54%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 13, 2026

Data Sources Report a data error